US5069216A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Silanized biodegradable super paramagnetic metal oxides as contrast agents for imaging the gastrointestinal tract
Assignee: Amag Pharmaceuticals Inc
•
Filing: 1989-09-19
•
Granted: 1991-12-03
•
Expires: 2009-09-19
Abstract
Abstract This invention relates to materials exhibiting certain magnetic and biological properties which make them uniquely suitable for use as magnetic resonance imaging (MRI) agents to enhance MR images of animal organs and tissues. More particularly, the invention relates to the in vivo use of biologically degradable and metabolizable superparamagnetic metal oxides as MR contrast agents. Depending on their preparation, these metal oxides are in the form of superparamagnetic particle dispersoids or superparamagnetic fluids where the suspending medium is a physiologically-acceptable carrier, and may be uncoated or surrounded by a polymeric coating to which biological molecules can be attached. These materials are administered to animals, including humans, by a variety of routes and the metal oxides therein collect in specific target organs to be imaged; in the case of coated particles, the biological molecules can be chosen to target specific organs or tissues. The biodistribution of the metal oxides in target organs or tissues results in a more detailed image of such organs or tissues because the metal oxides, due to their superparamagnetic properties, exert profound effects on the hydrogen nuclei responsible for the MR image. In addition, the dispersoids and fluids are quite stable and, in the case of the fluids, can even be subjected to autoclaving without impairing their utility. Furthermore, the materials are biodegradable and, in the case of iron oxide compounds, can eventually be incorporated into the subject's hemoglobin, making them useful in treating anemia. Thus, the materials are well-suited for in vivo use.
Inventors
- 👤 Ernest V. Groman
- 👤 Lee Josephson
- 👤 Jerome M. Lewis
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 07:45
CPC Classifications
G; G01; G01R; G01R33/00; G01R33/20; G01R33/44; G01R33/48; G01R33/54; G01R33/56; G01R33/5601; A; A61; A61K; A61K49/00; A61K49/06; A61K49/18; A61K49/1818; A61K49/1821; A61K49/1824; A61K49/1827; A61K49/1851; A61K49/1863; A61K49/1866; A61K49/1869; B; B82; B82Y; B82Y5/00; C; C08; C08G; C08G18/00; C08G18/06; C08G18/08; C08G18/16; C08G18/18; C08G18/1808; C08G18/1816; C08G18/1825; C08G18/20; C08G18/2009; C08G18/2036; C08G18/22; C08G18/24; C08G18/244; C08G18/246; C08G18/26; C08J; C08J9/00; C08J9/04; C08J9/12; C08J9/14; C08J9/143; C08J9/144; C08G2101/00; C08J2375/00; C08J2375/04
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
81 words
A method for obtaining an in vivo MR image of at least a portion of the gastrointestinal tract of an animal or human subject which comprises (a) administering enterally to such a subject an effective amount of a contrast agent in a physiologically acceptable carrier, which contrast agent comprises silanized aggregates of biodegradable superparamagnetic metal oxide crystals, said aggregates having an overall mean diameter of about 4000 angstroms or less as measured by light scattering; and (b) obtaining such MR image.
Claim 2
Independent Claim
81 words
A method for obtaining an in vivo MR image of at least a portion of the gastrointestinal tract of an animal or human subject which comprises (a) administering enterally to such a subject an effective amount of a contrast agent in a physiologically acceptable carrier, which contrast agent comprises silanized aggregates of biodegradable superparamagnetic metal oxide crystals, said aggregates having an overall mean diameter of about 4000 angstroms or less as measured by light scattering; and (b) obtaining such MR image.
Claim 3
Independent Claim
89 words
A method for obtaining an in vivo MR image of at least a portion of the gastrointestinal tract of an animal or human subject which comprises (a) administering enterally to such a subject an effective amount of a superparamagnetic fluid comprising a biodegradable superparamagnetic contrast agent in a physiologically acceptable buffered aqueous carrier, which contrast agent comprises silanized aggregates of biodegradable superparamagnetic metal oxide crystals, said aggregates having a overall mean diameter of about 4000 angstroms or less as measured by light scattering; and (b) obtaining such MR image.
Claim 4
Independent Claim
89 words
A method for obtaining an in vivo MR image of at least a portion of the gastrointestinal tract of an animal or human subject which comprises (a) administering enterally to such a subject an effective amount of a superparamagnetic fluid comprising a biodegradable superparamagnetic contrast agent in a physiologically acceptable buffered aqueous carrier, which contrast agent comprises silanized aggregates of biodegradable superparamagnetic metal oxide crystals, said aggregates having a overall mean diameter of about 4000 angstroms or less as measured by light scattering; and (b) obtaining such MR image.
Claim 5
Dependent Claim
27 words
The method of claim 1 or 2 in which the overall mean diameter of said aggregates is about 3000 angstroms or less as measured by light scattering.
Claim 6
Dependent Claim
27 words
The method of claim 1 or 2 in which the overall mean diameter of said aggregates is about 2000 angstroms or less as measured by light scattering.
Claim 7
Dependent Claim
27 words
The method of claim 1 or 2 in which the overall mean diameter of said aggregates is about 1000 angstroms or less as measured by light scattering.
Claim 8
Dependent Claim
24 words
The method of claim 1 or 2 in which said metal oxide is derived from a trivalent metal salt and a divalent metal salt.
Claim 9
Dependent Claim
24 words
The method of claim 1 or 2 in which said metal oxide is derived from a trivalent iron salt and a divalent metal salt.
Claim 10
Dependent Claim
16 words
The method of claim 1 or 2 in which said metal oxide is an iron oxide.
Claim 11
Dependent Claim
18 words
The method of claim 1 or 2 in which said contrast agent is administered to the subject orally.
Claim 12
Dependent Claim
19 words
The method of claim 1 or 2 in which said contrast agent is administered to the subject by intubation.
Claim 13
Dependent Claim
19 words
The method of claim 1 or 2 in which said contrast agent is administered to the subject by enema.
Claim 14
Dependent Claim
13 words
The method of claim 1 in which said physiologically acceptable carrier includes water.
Claim 15
Dependent Claim
17 words
The method of claim 2 in which said physiologically acceptable buffered aqueous carrier includes a polycarboxylic acid.
Claim 16
Dependent Claim
18 words
The method of claim 1 or 2 in which said portion of the gastrointestinal tract includes the esophagus.
Claim 17
Dependent Claim
18 words
The method of claim 1 or 2 in which said portion of the gastrointestinal tract includes the stomach.
Claim 18
Dependent Claim
19 words
The method of claim 1 or 2 in which said portion of the gastrointestinal tract includes the small intestine.
Claim 19
Dependent Claim
19 words
The method of claim 1 or 2 in which said portion of the gastrointestinal tract includes the large intestine.
Claim 20
Dependent Claim
18 words
The method of claim 1 or 2 in which said portion of the gastrointestinal tract includes the colon.
Claim 21
Dependent Claim
21 words
The method of claim 1 or 2 in which the silanizing agent used to silanize said aggregates is a polymerizable organosilane.
Claim 22
Dependent Claim
19 words
The method of claim 1 or 2 in which the silanizing agent used to silanize said aggregates is N-2-aminoethyl-3-aminopropyltrimethoxysilane.
Claim 23
Dependent Claim
27 words
The method of claim 1 or 2 in which said silanized aggregates further comprise covalently coupled biological molecules which are recognized by receptors in the gastrointestinal tract.
Claim 24
Dependent Claim
13 words
The method of claim 21 in which said biological molecule is an antibody.
Claim 25
Dependent Claim
16 words
The method of claim 21 in which said biological molecule is an antibody against neoplastic tissue.
References Cited (Backward Citations)
US3180741A
Cited
US3215572A
Cited
US3352638A
Cited
US3480555A
Cited
US3555143A
Cited
US3981776A
Cited
US3498748A
Cited
US3470067A
Cited
US3531413A
Cited
US3573980A
Cited
US3646346A
Cited
US3632512A
Cited
US3791930A
Cited
US3652761A
Cited
US4255492A
Cited
US3870645A
Cited
US3650698A
Cited
US3843773A
Cited
US3796660A
Cited
US3806449A
Cited
US3700595A
Cited
US3700555A
Cited
US3718594A
Cited
US4234437A
Cited
US3764540A
Cited
US4152210A
Cited
US3803044A
Cited
US3736500A
Cited
US3904540A
Cited
US3928709A
Cited
US3865627A
Cited
US3843540A
Cited
US4064292A
Cited
US4212903A
Cited
US3917538A
Cited
US3928220A
Cited
US4052326A
Cited
US3996407A
Cited
US3961990A
Cited
US3959032A
Cited
US4259358A
Cited
US3933997A
Cited
US4059716A
Cited
US4050962A
Cited
US4017303A
Cited
US4094804A
Cited
US4303636A
Cited
US4106488A
Cited
US4018882A
Cited
US3985649A
Cited
US4071610A
Cited
US3981844A
Cited
US3970518A
Cited
US4018886A
Cited
US4061727A
Cited
US4061725A
Cited
US4061726A
Cited
US4138383A
Cited
US4241176A
Cited
US4177317A
Cited
US4176172A
Cited
US4025448A
Cited
US4086174A
Cited
US4141687A
Cited
US4178416A
Cited
US4136683A
Cited
US4078971A
Cited
US4272510A
Cited
US4157323A
Cited
US4206094A
Cited
US4177253A
Cited
US4115534A
Cited
US4169804A
Cited
US4197220A
Cited
US4123396A
Cited
US4193866A
Cited
US4155748A
Cited
US4137342A
Cited
US4188302A
Cited
US4178171A
Cited
US4115535A
Cited
US4357259A
Cited
US4213959A
Cited
US4256434A
Cited
USRE30360E
Cited
US4221776A
Cited
US4267234A
Cited
US4209412A
Cited
US4198307A
Cited
US4226909A
Cited
US4165232A
Cited
US4219411A
Cited
US4219335A
Cited
US4197104A
Cited
US4276183A
Cited
US4335094A
Cited
US4208294A
Cited
US4287233A
Cited
US4296149A
Cited
US4230685A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-12-02 | 1995-06-03 | 1995-12-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-12-02 | 1999-06-03 | 1999-12-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-12-02 | 2003-06-03 | 2003-12-03 | $7700.00 | Window Closed / Lapsed |